Company Update (NYSE:ACT): Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product

[PR Newswire] – DUBLIN, Sept. 5, 2014 /PRNewswire/ — Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis’ application for ceftazidime-avibactam, its … . . . → Read More: Company Update (NYSE:ACT): Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product Similar Articles: Company Update: Actavis plc (NYSE:ACT) – Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline Company Update (NYSE:ACT): Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 Company Update (NYSE:ACT): Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI)